Clinical Trial Update: Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [EARLY_Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the safety, tolerability and preliminary efficacy of the PSMA-targeted radioligand 161Tb-LNC1011 in patients with metastatic castra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 161Tb-LNC1011

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: NOT_YET_RECRUITING